First Time Loading...
H

Hua Medicine
HKEX:2552

Watchlist Manager
Hua Medicine
HKEX:2552
Watchlist
Price: 1.59 HKD Market Closed
Updated: Apr 23, 2024

Intrinsic Value

Hua Medicine Ltd. provides drug discovery and development services. [ Read More ]

The intrinsic value of one Hua Medicine stock under the Base Case scenario is 2.14 HKD. Compared to the current market price of 1.59 HKD, Hua Medicine is Undervalued by 26%.

Key Points:
Intrinsic Value
Base Case
2.14 HKD
Undervaluation 26%
Intrinsic Value
Price
H
Worst Case
Base Case
Best Case

Valuation Backtest
Hua Medicine

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Hua Medicine stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Hua Medicine

Provide an overview of the primary business activities
of Hua Medicine.

What unique competitive advantages
does Hua Medicine hold over its rivals?

What risks and challenges
does Hua Medicine face in the near future?

Summarize the latest earnings call
of Hua Medicine.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Hua Medicine.

Provide P/S
for Hua Medicine.

Provide P/E
for Hua Medicine.

Provide P/OCF
for Hua Medicine.

Provide P/FCFE
for Hua Medicine.

Provide P/B
for Hua Medicine.

Provide EV/S
for Hua Medicine.

Provide EV/GP
for Hua Medicine.

Provide EV/EBITDA
for Hua Medicine.

Provide EV/EBIT
for Hua Medicine.

Provide EV/OCF
for Hua Medicine.

Provide EV/FCFF
for Hua Medicine.

Provide EV/IC
for Hua Medicine.

Show me price targets
for Hua Medicine made by professional analysts.

What are the Revenue projections
for Hua Medicine?

How accurate were the past Revenue estimates
for Hua Medicine?

What are the Net Income projections
for Hua Medicine?

How accurate were the past Net Income estimates
for Hua Medicine?

What are the EPS projections
for Hua Medicine?

How accurate were the past EPS estimates
for Hua Medicine?

What are the EBIT projections
for Hua Medicine?

How accurate were the past EBIT estimates
for Hua Medicine?

Compare the revenue forecasts
for Hua Medicine with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Hua Medicine and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Hua Medicine against its competitors.

Analyze the profit margins
(gross, operating, and net) of Hua Medicine compared to its peers.

Compare the P/E ratios
of Hua Medicine against its peers.

Discuss the investment returns and shareholder value creation
comparing Hua Medicine with its peers.

Analyze the financial leverage
of Hua Medicine compared to its main competitors.

Show all profitability ratios
for Hua Medicine.

Provide ROE
for Hua Medicine.

Provide ROA
for Hua Medicine.

Provide ROIC
for Hua Medicine.

Provide ROCE
for Hua Medicine.

Provide Gross Margin
for Hua Medicine.

Provide Operating Margin
for Hua Medicine.

Provide Net Margin
for Hua Medicine.

Provide FCF Margin
for Hua Medicine.

Show all solvency ratios
for Hua Medicine.

Provide D/E Ratio
for Hua Medicine.

Provide D/A Ratio
for Hua Medicine.

Provide Interest Coverage Ratio
for Hua Medicine.

Provide Altman Z-Score Ratio
for Hua Medicine.

Provide Quick Ratio
for Hua Medicine.

Provide Current Ratio
for Hua Medicine.

Provide Cash Ratio
for Hua Medicine.

What is the historical Revenue growth
over the last 5 years for Hua Medicine?

What is the historical Net Income growth
over the last 5 years for Hua Medicine?

What is the current Free Cash Flow
of Hua Medicine?

Discuss the annual earnings per share (EPS)
trend over the past five years for Hua Medicine.

Financials

Balance Sheet Decomposition
Hua Medicine

Current Assets 940.3m
Cash & Short-Term Investments 490.6m
Receivables 415.1m
Other Current Assets 34.6m
Non-Current Assets 181.2m
PP&E 139.7m
Intangibles 32m
Other Non-Current Assets 9.6m
Current Liabilities 188.4m
Accounts Payable 21m
Accrued Liabilities 39.8m
Short-Term Debt 33.9m
Other Current Liabilities 93.6m
Non-Current Liabilities 653.5m
Long-Term Debt 42.2m
Other Non-Current Liabilities 611.4m
Efficiency

Earnings Waterfall
Hua Medicine

Revenue
17.6m CNY
Cost of Revenue
-9.9m CNY
Gross Profit
7.7m CNY
Operating Expenses
-237.8m CNY
Operating Income
-230.1m CNY
Other Expenses
26.6m CNY
Net Income
-203.5m CNY

Free Cash Flow Analysis
Hua Medicine

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Hua Medicine's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

24/100
Profitability
Score

Hua Medicine's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Hua Medicine's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
59/100
Solvency
Score

Hua Medicine's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Hua Medicine

Wall Street analysts forecast Hua Medicine stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Hua Medicine is 3.59 HKD .

Lowest
Price Target
Not Available
Average
Price Target
3.59 HKD
126% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Hua Medicine

1M 1M
+3%
6M 6M
+6%
1Y 1Y
-50%
3Y 3Y
-68%
5Y 5Y
-77%
10Y 10Y
-81%
Annual Price Range
1.59
52w Low
1.3
52w High
3.2
Price Metrics
Average Annual Return -12.65%
Standard Deviation of Annual Returns 21.33%
Max Drawdown -84%
Shares Statistics
Market Capitalization 1.5B HKD
Shares Outstanding 978 723 296
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Hua Medicine

Country

China

Industry

Pharmaceuticals

Market Cap

1.5B HKD

Dividend Yield

0%

Description

Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.

Contact

SHANGHAI
Shanghai
Hua Medicine, Building 2, Lane 36, Xuelin Road, Pudong New Area
https://www.huamedicine.com

IPO

2018-09-14

Employees

146

Officers

Founder, CEO & Executive Director
Dr. Li Chen Ph.D.
Executive VP, Chief Strategy Officer & Executive Director
Mr. Chien Cheng Lin J.D.
Vice President of Operation Department
Dr. Di Hong
Director of Corporate Finance
Emily Yeh
CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA
Dr. Fuxing Tang Ph.D.
Chief Scientific Officer
Dr. Changhong Li Ph.D.
Show More
Head of IR
Mr. Chengde Wang
VP and Head of Commercial Strategy & Marketing
Ms. Wenjie Xu M.B.A.
Senior VP of Pharma Development & Chief Medical Officer ? China and Executive Director
Dr. Yi Zhang M.D., Ph.D.
Senior VP of Chemical Manufacturing Control Department & Chief Manufacturing Officer
Dr. Jin She Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one Hua Medicine stock?

The intrinsic value of one Hua Medicine stock under the Base Case scenario is 2.14 HKD.

Is Hua Medicine stock undervalued or overvalued?

Compared to the current market price of 1.59 HKD, Hua Medicine is Undervalued by 26%.